Danaher 2009 Annual Report Download - page 9

Table of Contents
Life Sciences and Diagnostics
Acute Care. Our acute care diagnostics business was created in 2004 through the acquisition of Radiometer and has since been supplemented by
additional acquisitions. Our acute care diagnostics business is a leading worldwide provider of blood gas and immunochemistry instruments and related
consumables and services. Sold under the RADIOMETER brand, these instruments are used to rapidly measure critical immunochemistry parameters
including blood gases and diagnostic protein levels. Typical users of Radiometer products include hospital central laboratories, intensive care units, hospital
operating rooms, and hospital emergency rooms. Customers in this industry select products based on a number of factors, including the accuracy and speed
of the product, the scope of tests that can be performed, the product’s ability to enhance productivity and the other factors described under “—Competition.”
Manufacturing facilities are located in Europe and North America, and sales are made primarily through our direct sales personnel and, in some countries,
through distributors.
Pathology Diagnostics. We established our pathology diagnostics business in 2005 through the acquisition of Leica Microsystems and have expanded
the business through subsequent acquisitions, including Vision Systems in 2006 and Surgipath Medical Industries, Inc. and CoreTech in 2008. Our
pathology diagnostics business is a leading global provider of instrumentation and related consumables used throughout the workflow of a pathology
laboratory. Our pathology diagnostics products include:
• tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables;
• chemical and immuno-staining instruments, reagents, antibodies and consumables; and
• slide coverslipping and slide/cassette marking instruments.
Typical users of our pathology diagnostic products include pathologists, lab managers and researchers. Customers in this industry select products based on a
number of factors, including operational reliability, the product’s ability to produce consistent samples and the breadth of the offered reagent portfolio, as well
as the other factors described under “—Competition.” We generally market our products under the LEICA and SURGIPATH brands. Manufacturing facilities
are located in the U.S., Europe, China and Australia. The businesses sell to customers primarily through direct sales personnel.
Life Sciences Instrumentation. Our life sciences instrumentation business was created in 2005 through the acquisition of Leica Microsystems and has
been expanded through subsequent acquisitions, including the acquistions of AB Sciex and Molecular Devices in 2010.
Our Leica business is a leading global provider of professional microscopes designed to manipulate, preserve and capture images of, and enhance the user’s
visualization of, microscopic structures. Our life sciences products include:
• laser scanning (confocal) microscopes;
• compound microscopes and related equipment;
• surgical and other stereo microscopes; and
• specimen preparation products for electron microscopy.
Typical users of our Leica products include research, medical and surgical professionals operating in research and pathology laboratories, academic settings
and surgical theaters. Customers in this industry select products based on a number of factors, including product performance and ergonomics, the product’s
capacity to enhance productivity, and the other factors described under “—Competition.” We generally market our products under the LEICA brand.
Manufacturing facilities are located in Europe, Australia, Asia and the United States. The businesses sell to customers through a combination of our direct
sales personnel, independent representatives and independent distributors.
AB Sciex is a leading global supplier of high-end mass spectrometers, and Molecular Devices is a leading global supplier of other high-performance
bioanalytical measurement systems.
7
Source: DANAHER CORP /DE/, 10-K, February 24, 2010 Powered by Morningstar® Document Research℠
The information contained herein may not be copied, adapted or distributed and is not warranted to be accurate, complete or timely. The user assumes all risks for any damages or losses arising from any use of this information,
except to the extent such damages or losses cannot be limited or excluded by applicable law. Past financial performance is no guarantee of future results.